The first of two late-stage trials of a new antibiotic being developed by Cubist Pharmaceuticals shows the drug works better than the existing standard of care, Levaquin, for treating complicated urinary tract infections.
The first of two late-stage trials of a new antibiotic being developed by Cubist Pharmaceuticals shows the drug works better than the existing standard of care, Levaquin, for treating complicated urinary tract infections.
